



# Optimising the Utility of *In Vitro* Tests for the Diagnosis of Drug Allergy: Insights from a Clinical Perspective

Marina Sabaté-Brescó, PhD<sup>1,2</sup>

Paola Leonor Quan, MD<sup>1\*</sup>

María José Goikoetxea, MD, PhD<sup>1,2,3</sup>

## Address

<sup>1</sup>Department of Allergy and Clinical Immunology, Clínica Universidad de Navarra, 31008 Pamplona, Spain  
Email: pquan@unav.es

<sup>2</sup>Instituto de Investigación Sanitaria de Navarra (IdiSNA), Pamplona, Spain

<sup>3</sup>RICORS: Red De Enfermedades Inflammatorias (REI) — RD21/0002/0028, Madrid, Spain

Published online: 11 July 2023

© The Author(s) 2023

**Keywords** Drug hypersensitivity reactions · Drug allergy · *In vitro* diagnostic tests · Drug sIgE · Basophil activation test · Lymphocyte transformation test

## Abstract

**Purpose of review** To outline currently validated *in vitro* tests for the diagnosis of drug hypersensitivity reactions (DHRs) and to provide useful strategies to optimise the utility of these tools.

**Recent findings** Regarding *in vitro* tests for DHR, the main concern, at present, is low sensitivity. Thus, most of the efforts are currently directed towards improving the existing techniques and developing new assays with better diagnostic performance.

**Summary** The management of DHRs is particularly challenging. Current strategies for diagnosis are focused on taking a thorough clinical history, evaluating sensitization using skin testing and performing supervised challenges. *In vitro* tests may potentially add information to the diagnostic algorithms for the management of DHRs. The presently available assays, however, pose significant limitations in terms of availability and validation. Maximizing their yield and accuracy, therefore, requires a tailored approach, focused on an appropriate clinical characterisation of the reaction. The time elapsed between drug

administration and symptom presentation, as well as symptom duration, should be closely taken into consideration. In this review, existing validated *in vitro* techniques that may support the diagnosis of both immediate and non-immediate DHRs are summarised. Clues for optimizing their diagnostic yield are given.

## Introduction

The evaluation of hypersensitivity reactions to drugs involves three main strategies: accurately reviewing the patient's clinical history [1•], conducting diagnostic tests (skin tests and/or *in vitro* tests) [2] and performing drug challenge tests [3]. Challenge tests are currently the gold standard for diagnosis, but they often involve significant risks, especially in patients who have received multiple drugs in the context of an adverse reaction and/or patients with multiple comorbidities. Diagnostic evaluations based on *in vivo* tests, although accessible, do not offer perfect sensitivity rates. Thus, *in vitro* techniques may provide an interesting complement for diagnosis before conducting challenges and may even be considered as an alternative, particularly in cases with a history of a life-threatening reaction.


However, laboratory tests in drug allergy diagnosis have limitations: they confer moderate sensitivity, availability is not guaranteed for all drugs, and some of the techniques are only available in specialised laboratories [4••]. Furthermore, limited evidence for some drugs results in a restricted validation for routinely use [4••, 5••]. Maximizing their potential utility, therefore, requires a tailored approach, focused on an appropriate clinical characterization of the reaction. In this review, the existing evidence backing the currently available *in vitro* tests for drug hypersensitivity reactions (DHR) is summarised. Additionally, useful tips to optimise the yield of these tools are provided for the clinician.

## *In vitro* tests should be requested according to the type of reaction: clinical clues

The main objectives in the management of a DHR after its treatment and resolution are as follows: to search for the culprit drug — in order to instruct future avoidance, when possible — and to clarify tolerance to alternative treatments for the patient. Frequently, the patient is only evaluated by an allergist once the reaction has resolved. Two types of *in vitro* tests are available to meet these objectives: those which help characterise the type of reaction during the acute phase (focused on cells involved and mediators released) and those applied after reaction resolution, to seek the culprit drug. An approach that considers the possible mechanism involved in a reaction is necessary to select the best *in vitro* techniques and to optimise their performance. Thus, reactions should be properly characterised during the acute phase, if possible, or based on the patient report [1•].

Depending on the time passed between the consumption of the drug and symptom onset, reactions are classified as suggestive of either immediate hypersensitivity (0–6 h) or non-immediate hypersensitivity (hours–days) [2]. However, this classification is often difficult to apply, for instance, in the case of reactions occurring 1–6 h after drug intake, which have often

**Currently Existing In Vitro Tests for the Diagnosis of Drug Hypersensitivity:**  
 In which clinical context is each test useful?



**Fig. 1** Most commonly used *in vitro* tests for the diagnosis of drug hypersensitivity.

been termed “accelerated drug reactions” [6]. Also, the time elapsed from the administration of the culprit drug to the onset of symptoms is often difficult to determine in patients who received several drugs in the context of a reaction.

To simplify, in this review, DHRs will be divided into immediate drug reactions (IDHR) (symptoms appearing in the first 6 h after drug intake) and non-immediate drug reactions (NIDHR) (symptoms appearing more than 6 h after drug intake). Clinical features indicate differences between these two types of reactions, since IDHR have a rapid onset and evolve very quickly (in less than an hour, the patient can turn from being asymptomatic to being in life-threatening condition), whereas NIDHR normally show persistent (lasting longer than 24 h) skin lesions (maculo-papules, pustules, blisters...) that can be accompanied by systemic alterations such as hepatotoxicity, eosinophilia, or lymphadenopathy (Fig. 1). In the case of IDHR, different clinical patterns can be observed: type 1 reactions (IgE or non-IgE mediated) typically manifesting with urticaria, angioedema, bronchial hyperreactivity or even anaphylaxis and cytokine storm-like reactions, which can also result in anaphylaxis but may initially present with

different clinical characteristics such as fever, chills and musculoskeletal pain [7•] (Fig. 1).

## Acute phase mediators aid in the identification of the reaction mechanism

Certain blood markers, when measured during the acute phase of a reaction, help characterise the mechanism underlying a DHR. In IDHR, for example, mast cell and basophil mediators, such as tryptase or histamine, are released, suggesting a type 1 reaction [7•]. On the other hand, in cytokine storm-like reactions, T cells and other cell types release cytokines, such as tumour necrosis factor (TNF)- $\alpha$  and interleukin (IL)-6 [8]. Prostaglandins, leukotrienes (LT) C4 and LTD4 are also increased in type 1 non-IgE reactions induced by nonsteroidal anti-inflammatory drugs (NSAIDs) [9], but the use of these markers for diagnosis has not been validated. Although the measurement of an increase in histamine levels showed high sensitivity in perioperative immediate reactions [10], its specificity is not very high [11] and sample extraction and preservation must be performed extremely quickly due to the short half-life of the molecule [12]. Tryptase measurement by means of the automatized fluorescence enzyme immunoassay (FEIA) system, on the other hand, is a validated technique, which is easily performed. It has established tryptase as the main mediator measured for acute phase IDHR and shows high sensitivity and high specificity. The latter can vary depending on the applied cut-off point and is influenced by the comparison between basal levels and levels measured within 2 h after the reaction [13]. Moreover, tryptase has been proposed as a specific acute phase marker for IgE-mediated reactions [10, 14]. Finally, although the sensitivity and specificity for the detection of interleukin-6 have not been evaluated for IDHR, an elevation of interleukin-6 levels, along with the absence of a relevant increase in tryptase levels, in an IDHR presenting with symptoms such as fever, chills, or musculoskeletal pain, could be suggestive of a cytokine storm-like reaction [15•].

Importantly, these acute phase biomarkers should always be measured during the reaction and should be compared to basal values, measured at least 24 h after symptom resolution [10, 16]. Alterations of the mast cell population, hematologic diseases and/or genetic disorders, for instance, may increase resting serum tryptase [17], and it is important to consider these entities in every patient's differential diagnosis, particularly if elevated tryptase levels have been documented.

The clinical evaluation of NIDHR can be challenging, especially if systemic symptoms are present, and therefore, a broad differential diagnosis should be considered. In the context of an NIDHR, recommended ancillary tests include peripheral blood count, serologies for concomitant, pre-existing or reactivated infectious disease, liver enzymes, renal function and acute markers for inflammation. Although some biomarkers have been proposed for the acute phase in NIDHR, validation studies and technique

**Table 1. Global sensitivity and specificity values for different drugs in sIgE and BAT**

Specific IgE			
Drug	Se	Sp	References
β-lactams	0–85%	54–98%	[20, 22•, 23, 25–27, 60]
Atracurium (RUO)	57.1%	100%	[61]
Rocuronium (RUO)	83–92%	68%	[62]
Morphine	78–84%	85–90.7%	[62, 63]
Suxamethonium	44%	100%	[62]
Chlorhexidine	91.6%	100%	[64]
Basophil activation test			
Drugs	Se	Sp	References
β-lactams	22–55%	89–100%	[25, 65–68]
AMX	13–52%	79–100%	[70, 71, 73–76]
AMX/CLAV	42.9–62%	80–93%	[75, 77]
Quinolones	0–100%	77.8–100%	[62, 72, 78–81]
Neuromuscular blockers	36–86%	81–100%	[82–87]
Rocuronium	80–100%	96–100%	[88–90]
Radiocontrast media	25–62.5%	89–100%	[69, 91, 92]
Platinum-containing chemotherapeutic drugs	73%	100%	[93]
Pyrazolones	42.3–70%	85.7–100%	[86, 94, 95]

AMX amoxicillin, CLAV clavulanic acid, RUO research use only, Se sensitivity, Sp specificity. Based on Decuyper et al. (2017) [4••], Mayorga et al. (2017) [49], Elst et al. (2021) [34•]

availability are still necessary [18] Regarding other available tests for these types of reactions, associations between certain HLA alleles and severe drug delayed reactions have been described [19]. Identifying certain HLA alleles, depending on ethnicity and the drug involved, can be helpful in characterising a reaction during the acute phase, but the main utility of these tests may rest in the prevention of NIDHR [19].

## Tests that may aid in the discovery of the culprit drug

### Immediate hypersensitivity reactions mediated by immunoglobulin E (IgE)

#### Detection of specific IgE against drugs

Specific IgE (sIgE) can potentially be used to orient the diagnosis of IgE-mediated IDHR, but it can only be measured against a limited number of drugs. Tests to determine the presence of sIgE to drugs are based on enzyme immunoassays, which employ the suspected drug, immobilised in a solid phase, to capture the immunoglobulin. However, since drugs

are haptens, the drug needs to be bound to carriers such as poly-L-lysine (PLL), human serum albumin (HSA), amino-aliphatic spacers, or dendrimer structures. The most widely used commercial system for the determination of drug sIgE is the FEIA (ImmunoCAP Thermo Fisher, Uppsala, Sweden), which uses PLL as a carrier. Furthermore, evidence for the use of sIgE-FEIA against drugs is mostly restricted to  $\beta$ -lactams (only available to benzylpenicillin, penicillin V, amoxicillin, ampicillin and cefaclor). In general, sIgEs against drugs show low sensitivity, which can be influenced by the severity of the IDHR [20], and the time elapsed since the reaction when the test is performed [21]. Higher values have been observed for specificity than for sensitivity [22•, 23–25], although some authors have also reported low specificity in patients with high levels of total IgE [26]. The currently available data for the diagnostic performance of sIgE against drugs by FEIA is summarized in Table 1. The low sensitivity values, together with the false-positive rates for penicillin G in populations with selective allergy to aminopenicillins, suggest that ImmunoCAP is a diagnostic tool with limitations when evaluating subjects with a suspected type 1 hypersensitivity reaction to penicillins [22•].

Different strategies have been proposed to improve the sensitivity and specificity of sIgE-FEIA (especially for beta-lactams), such as decreasing the cut-off point to 0.01 kU<sub>A</sub>/L [26] or using an sIgE to penicillins/total IgE ratio [27], with less than promising results [22•]. Alternate techniques for the detection of sIgE against drugs have been developed, focused on new drug carriers (i.e. dendrimers [28], detection systems [29, 30], or calibrators improvement [31]).

---

### *Basophil activation test*

Among the cellular techniques employed for the diagnosis of allergic disease, the basophil activation test (BAT) is the most established and widespread one to date. The main difference between BAT and assays for the detection of specific IgE is that the former implies the presence of more than antibodies: it demonstrates whether the allergen is capable of activating an effector cell.

Basophils constitute a minor fraction of all leukocytes in peripheral blood (less than 1%) and, upon IgE cross-linking by its antigen, can activate and degranulate, expelling the preformed content from their granules (histamine, leukotrienes...), as well as *de novo* synthesised mediators [32]. The incubation of these cells with the suspected drug may trigger this activation cascade, which induces intracytoplasmic fusion of granules within the cell and fusion of these granules with the plasmatic membrane. Thus, molecules from the granular membrane, such as CD63, are expressed in the basophil's membrane upon activation. The expression of CD63 is therefore correlated with degranulation, rendering it an ideal marker for basophil activation that can be easily detected with flow cytometry. It is also possible to differentiate basophil activation/degranulation using other markers such as CD203c or CD107a or with the use of avidin [32, 33]. The functionality of the cells can additionally be explored through the quantification of released mediators or through assessing intracellular pathways (e.g.

**Table 2. Most common *in vitro* tests for drug allergy with its clinical and technical considerations**

	Sample timing (after DHR)	Treatment influence on the technique	Type of sample and stability	Technique performance time	Technical requirements	Other considerations
sIgE (FEIA)	<b>After the reaction (better in the first year after reaction)</b> [21]	Not described Oma: Increases tIgE levels and often sIgE	Sera/plasma, stable over several months when frozen < -20 °C	Hours	Specialised equipment (broadly available)	Automated
Tryptase (FEIA)	At the reaction time (and/or +2 h), basal sample	Not described	Sera/plasma, stable over several months when frozen < -20 °C	Hours	Specialised equipment (broadly available)	Automated
BAT	Not acute, at least 1 month post reaction and ideally during the first year after the reaction	SC: yes, retire 3 weeks prior test [96, 97] Oma: may alter BAT results [98]	Anticoagulated blood, stable for 24–48 h	Hours	Trained personnel Flow cytometry equipment	Not automated
LTT	Not acute [53], >2–4 weeks post reaction and ideally during the first year after the reaction. May not be applicable to all clinical manifestations	SC: yes, wash up period not determined Immunosuppressive drugs: may impair lymphocyte proliferation [96]	Anticoagulated blood (most often heparin), stable for 24 h	5 to 10 days	Trained personnel. Cell culture and other specialised equipment (depending on read-out) Radioactivity use although alternatives are available	Not automated

BAT basophil activation test, DHR drug hypersensitivity reaction, FEIA: fluoro enzyme immunoassay, LTT lymphocyte transformation test, SC systemic corticosteroids, Oma omalizumab, sIgE specific IgE, tIgE total IgE

phosphorylation of signalling molecules or intracellular calcium) [32, 34•]. Assays include one or more positive controls (with anti-IgE or anti-FcεRI, fMLP...) to prove capacity of the employed basophils for degranulation or viability. Ten to 20% of the population are nonresponders, with basophils that do not degranulate upon IgE pathway stimulation. The best way to interpret data in these cases is a matter of controversy.

Activated basophils are commonly identified by measuring the percentage of cells positive for CD63 and/or the change in mean fluorescence intensity (MFI) given by CD203c when compared to a negative control (unstimulated basophils). When using CD63, a cut-off point of 5% (proportion of activated basophils) is usually employed to define drug-specific cell activation, although some centres use other percentages or cut-off values based on ratios. When using CD203c, other cut-off values are applied [35]. A proper calculation involves the use of a ROC curve for each protocol and drug.

BAT shows variable sensitivity and specificity results for the study of allergy to certain drug groups (Table 1) [35], although, in general, it provides moderate to high specificity [33]. The usefulness of this technique is highly dependent on its appropriate application by the clinician, since it should only be requested when an IgE-mediated hypersensitivity reaction is suspected.

Several technical factors may also influence the technique performance and the quality of the results of the test [36]. These include the sampling conditions (Table 2), the use of relevant allergens and the use of a proper technique. The basophil-gating strategies employed during flow cytometry analysis, the markers utilised for cell identification (commonly CCR3 also known as CD193, CD123 +/HLA-DR-, CD203c, or IgE), and the markers used for the detection of activated cells (commonly CD63 or CD203c) may alter the findings obtained from this test [33]. Drug concentrations should be established for each method and, in many cases, can be found published in the literature.

Apart from technical aspects, other factors need to be considered, such as the time passed between the reaction and the extraction of the blood sample (Table 2). Ideally, the test should be performed at least 1 month (refractory period) and less than 1 year after the reaction. It is also important to consider the medication used by the patient who is being tested. Corticosteroids have been shown to reduce basophil degranulation capacity, and thus, it is recommended that systemic steroids should be suspended 3 weeks before the test, while topical treatments with steroids do not influence the result [33].

A variant of BAT, which would be generally performed with patients' own cells, consists of a passive sensitization of basophils from healthy donors. Briefly, IgE is removed from the basophil surface, and cells are further incubated with sera from allergic patients, to sensitise them with the patient's IgE. Afterwards, BAT is performed. Even though it is mainly used in allergy as a research tool, it has been successfully employed in drug-allergic patients, and, for some drugs, it has depicted sensitivity and specificity values comparable to the classic BAT [37, 38].



### *Mast cell activation test*

Mast cells (MCs), a tissue-resident cell type, are considered the main effector cells in most IDHR. Like basophils, MC express FcεRI in their surface and are coated with IgE molecules that, upon cross-linking, can cause MC degranulation.

In a similar fashion to the BAT, the mast cell activation test (MAT) aims to expose these cells to the suspected allergen. Its application is still limited, mainly due to technical challenges, to the difficulty in obtaining cells to perform the assays and to its costs. Different strategies exist to obtain MC, such as differentiating the cells from peripheral blood progenitors [39, 40], or the use of cell lines [33, 41•]. After obtaining the cells, they need to be sensitised with the patient's sera and further exposed to the suspected allergens. As in BAT, CD63 can be used to assess MC degranulation, as well as other cell surface markers (e.g. CD203c, CD107a) or to quantify the release of mediators such as β-hexosaminidase.

Due to their accessibility, basophils have traditionally been used as effector cells for allergy functional assays, although evidence suggests that using mast cells for the evaluation of drug-dependent activation *in vitro* may be more effective than BAT and other established diagnostic techniques [39]. The use of mast cells is also reasonable when detecting hypersensitivity reactions mediated by mechanisms not involving IgE, such as reactions mediated by the Mas-related G protein-coupled receptor X2 (MRGPRX2) [42].

## ***In vitro* tests available for in delayed, or non-immediate, drug hypersensitivity**

### *Lymphocyte transformation test*

The main technique available for the diagnosis of NIDHR is a cellular technique, based on lymphocyte proliferation after stimulation with suspected allergens, named lymphocyte transformation test (LTT) [43–45].

LTT addresses drug-specific T cell — the main cell type orchestrating DHR — proliferation. In brief, lymphocytes are isolated from venous blood and are cultured with the suspected drug, or drugs, for several days, most often 5 to 7. The goal is to observe cell proliferation greater than the basal level, which should occur in the case of a positive test. Several techniques allow the quantification of cell proliferation. Historically, determination of radiolabeled thymidine (3H-thymidine) incorporation has been used to study proliferation, but, due to its technical requirements and risks, its use is declining. The use of flow cytometry to monitor fluorescently labelled cells (with carboxyfluorescein succinimidyl ester, for example) or the use of non-radiolabeled agents incorporating into DNA (such as BrdU) is gaining relevance [46, 47].

In general, LTT has a good specificity (63–100%) and a low to moderate sensitivity (25–89%), although data differ for different drugs and clinical phenotypes [48, 49]. Several studies have noted that specificity and sensitivity are improved when considering only mild to moderate reactions [49]. A limitation of most studies is that, due to the risks encompassed in drug provocation

tests, the gold standard to estimate specificity and sensitivity is often based on algorithms [50]. Approaches to improve sensitivity [46], like the use of antigen-presenting cells [51] or the removal of regulatory T-cell [47, 52], have been successfully applied.

Test performance is influenced by different factors (Table 2), such as the time elapsed after the moment of the reaction when the extraction is performed. Although the optimal moment to conduct the test is not fully elucidated, evidence suggests that the acute phase should be avoided (<2–4 weeks), and that waiting for too long (>12–36 months) also increases the chances of a negative result [53, 54]. However, some studies suggest that, for certain clinical syndromes, the acute phase may be better to perform LTT, so more data is still needed [54]. Another parameter to consider is patient treatment, as they may impair T-cell proliferation. In general, avoidance of corticosteroid treatment (or at most, the use of low doses) is recommended at the moment of sample extraction [53, 55]. Other immunosuppressive drugs may also interfere with the test, although more evidence would be needed to establish indications. LTT is based on specific lymphocyte responses. Thus, the presence of lymphopenia should be noted since, in patients with low counts, the performance of the test may be not optimal [55]. Finally, it is important to keep in mind that, for some clinical syndromes of NIDHR, LTT seems to have a better performance, although the lack of standardisation makes available data difficult to interpret. Drug reaction with eosinophilia and systemic symptoms (DRESS)/drug-induced hypersensitivity syndrome (DIHS) often shows a good performance for LTT, while for maculopapular exanthema (MPE), results are variable among studies. Doubtful results have been observed for Stevens-Johnson syndrome (SJS)/toxic epidermal necrolysis (TEN) or for fixed drug exanthemas, where the number of affected cells in circulation is probably very low [54–57].

Although proliferation is the main read-out method used in LTT, other strategies can be used independently or in combination with proliferation, such as the detection of activation markers with flow cytometry (e.g. CD69) [46, 58].

---

#### *Other in vitro tests for non-immediate drug hypersensitivity*

Alternative *in vitro* tests for delayed drug reactions include the enzyme-linked immunosorbent spot assay (ELISpot) technique or the quantification of cytokines and cytotoxic mediators. ELISpot quantifies cells producing one or several mediators of interest, such as interferon (IFN)- $\gamma$ , IL-5 or granzyme B [46, 49]. Another alternative approach is the quantification of cytokines and/or cytotoxic mediators in culture supernatant after culturing lymphocytes with the suspected drug (mostly interferon- $\gamma$  but also IL-5, IL-2, IL-10, granulysin or granzyme B). The quantification is often performed with ELISA but can be conducted using other approaches [46, 52]. Both ELISpot and ELISA have shown sensitivities and specificities comparable to those obtained with LTT. In a recent meta-analysis, ELISA was reported to be more sensitive than classical LTT, although heterogeneity of the data remains a great challenge when comparing techniques [54].

## Considerations for the future of *in vitro* diagnostic tests

Since *in vitro* tests for diagnosis are considered healthcare products, reviewing current legislation regarding these methods is relevant. The *In vitro* Diagnostic Medical Devices Regulation (IVDR) is a new legislation providing a regulatory framework for all *in vitro* diagnostic tests within the European Union. It was established on May 25, 2017. This date marks the beginning of a 5-year transition period for manufacturers and economic operators, since IVDR is replacing the 98/79/CE Directive, which applied to *in vitro* diagnostic devices.

Adaptation of *in vitro* diagnostic tests in drug allergy to the IVDR regulation is challenging, since commercially available products for diagnosis which meet its requirements scarcely exist. Techniques developed in the laboratory should meet a specific set of requirements and should be backed by extensive documentation. Suggestions to validate these cellular techniques to incorporate them in clinical practice include analytical validation studies and a continuous monitoring of methodological quality [59•]. Significant efforts are required from each laboratory but also a collaboration that aids in the development of standardised techniques and the establishment of robust quality controls.

## Conclusion

Diagnosis of drug hypersensitivity reactions poses many challenges, especially when it comes to discovering the culprit drug. *In vitro* tests can be used to support this process. However, it is important to consider their limitations. The decision to use them should always involve a careful consideration of clinical symptoms, history and skin testing data available from patients. In addition, to maximise the potential benefit from such tools, it is important to carefully select the ideal settings for their applications. There is still a need for improving sensitivity in most of the techniques and specificity for certain drugs. Furthermore, several tests require specialised equipment and trained personnel and thus are not broadly available. It is essential to construct networks of specialised centres to expand the knowledge of these techniques and to adequately validate them in as many centres as possible.

## Acknowledgements

Figures were created using BioRender.com.

## Funding

Open Access funding provided thanks to the CRUE-CSIC agreement with Springer Nature.

## Declarations

### Conflict of Interest

The authors declare no competing interests.

### Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

### Open Access

This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

## References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as:

- Of importance
- Of major importance

1. • García-Avilés C, Martín-Lázaro J, Gastaminza G. How to take a good clinical history in cases of allergic reactions to medications. *J Investig Allergol Clin Immunol*. 2022;32(3):181–90.

This review focuses on the importance of taking a good clinical history as an essential step in addressing drug sensitivity reactions and selecting diagnostic tests.

2. Brockow K, Garvey LH, Aberer W, Atanaskovic-Markovic M, Barbaud A, Bilo MB, et al. Skin test concentrations for systemically administered drugs – an ENDA/EAACI Drug Allergy Interest Group position paper. *Allergy*. 2013;68(6):702–12.
3. Chiriac AM, Demoly P. Drug provocation tests: up-date and novel approaches. *Allergy Asthma Clin Immunol*. 2013;9(1):1–5.
4. •• Decuyper II, Mangodt EA, Van Gasse AL, Claesen K, Uyttebroek A, Faber M, et al. In vitro diagnosis of immediate drug hypersensitivity Anno 2017: potentials and limitations. *Drugs R D*. 2017;17(2):265–78.

Review of the potentials and limitations of *in vitro* tests for the diagnosis of drug hypersensitivity.

5. •• Mayorga C, Celik G, Rouzaire P, Whitaker P, Bonadonna P, Rodrigues-Cernadas J, et al. In vitro

tests for drug hypersensitivity reactions: an ENDA/EAACI Drug Allergy Interest Group position paper. *Allergy*. 2016;71(8):1103–34.

Position paper from the ENDA/EAACI Drug Allergy Interest Group on *in vitro* tests for the diagnosis of drug hypersensitivity.

6. Torres MJ, Salas M, Ariza A, Fernández TD. Understanding the mechanisms in accelerated drug reactions. *Curr Opin Allergy Clin Immunol*. 2023;16(4):308–14.
7. • Castells M. Diagnosis and management of anaphylaxis in precision medicine. *Journal of Allergy and Clinical Immunology*. 2017;140(2):321–33.

This review addresses the diagnosis of anaphylaxis and provides insights of its mechanisms and endotypes. It addresses biomarkers of anaphylaxis that may aid in the definition of the mechanism behind drug hypersensitivity.

8. Santini D, Tonini G, Salerno A, Vincenzi B, Patti G, Battistoni F, et al. Idiosyncratic reaction after oxaliplatin infusion [3]. *Ann Oncol*. 2001;12(1):132–3.
9. Kowalski ML, Asero R, Bavbek S, Blanca M, Blanca-Lopez N, Bochenek G, et al. Classification

- and practical approach to the diagnosis and management of hypersensitivity to non-steroidal anti-inflammatory drugs. *Allergy*. 2013;68(10):1219–32.
10. Berroa F, Lafuente A, Javaloyes G, Ferrer M, Moncada R, Goikoetxea MJ, et al. The usefulness of plasma histamine and different tryptase cut-off points in the diagnosis of perianaesthetic hypersensitivity reactions. *Clin Exp Allergy*. 2014;44(2):270–7.
  11. Mertes PM, Laxenaire MC, Alla F, Peranesthésiques G detudes des RA. Anaphylactic and anaphylactoid reactions occurring during anesthesia in France in 1999–2000. *Anesthesiology*. 2003; 99(3):536–45.
  12. Gueant J, Aimone-Gastin I, Namour I, Laroche D, Bellou A, Laxenaire M. Diagnosis and pathogenesis of the anaphylactic and anaphylactoid reactions to anaesthetics - PubMed. *Clin Exp Allergy*. 1998;28(Supp 4):65–70.
  13. Srisuwachari W, Tacquard CA, Borushko A, Viville S, Stenger R, Ehrhard Y, et al. Diagnostic performance of serial serum total tryptase measurement to differentiate positive from negative allergy testing among patients with suspected perioperative hypersensitivity. *Clin Exp Allergy*. 2022;52(2):334–44.
  14. Fisher MM, Baldo BA. Mast cell tryptase in anaesthetic anaphylactoid reactions. *Br J Anaesth*. 1998 [cited 2023 Apr 5];80(1):26–9. Available from: <https://pubmed.ncbi.nlm.nih.gov/9505773/>
  - 15• de las Vecillas L, Castells M. Non-IgE adverse reactions to biologics. *J Allergy Clin Immunol*. 2021;147(4):1204–6.
- Manuscript reviewing non-IgE-mediated adverse reactions to drugs.
16. Ulrich-Pur H, Fiebiger WCC, Schüll B, Kornek G V., Scheithauer W, Raderer M. Oxaliplatin-induced fever and release of IL-6. *Oncology*. 2000 [cited 2023 Apr 3];59(3):187–9.
  17. Lyons JJ, Greiner G, Hoermann G, Metcalfe DD. Incorporating tryptase genotyping into the workup and diagnosis of mast cell diseases and reactions. *J Allergy Clin Immunol: In Practice*. 2022;10(8):1964–73.
  18. Yoshioka M, Sawada Y, Nakamura M. Diagnostic tools and biomarkers for severe drug eruptions. *Int J Mol Sci*. 2021;22(14):22.
  19. Phillips EJ, Chung WH, Mockenhaupt M, Roujeau JC, Mallal SA. Drug hypersensitivity: pharmacogenetics and clinical syndromes. *J Allergy Clin Immunol*. 2011;127(3 Suppl):S60.
  20. Fontaine C, Mayorga C, Bousquet PJ, Arnoux B, Torres MJ, Blanca M, et al. Relevance of the determination of serum-specific IgE antibodies in the diagnosis of immediate  $\beta$ -lactam allergy. *Allergy*. 2007;62(1):47–52.
  21. Fernández TD, Torres MJ, Blanca-López N, Rodríguez-Bada JL, Gomez E, Canto G, et al. Negativization rates of IgE radioimmunoassay and basophil activation test in immediate reactions to penicillins. *Allergy*. 2009;64(2):242–8.
  - 22• Ariza A, Mayorga C, Bogas G, Gaeta F, Salas M, Valluzzi RL, Labella M, Pérez-Sánchez N, Caruso C, Molina A, et al. Detection of serum-specific IgE by fluoro-enzyme immunoassay for diagnosing type I hypersensitivity reactions to penicillins. *Int J of Mol Sci*. 2022;23(13):6992. <https://doi.org/10.3390/ijms23136992>
  23. Sanz ML, Garcia BE, Prieto I, Tabar A, Oehling A. Specific IgE determination in the diagnosis of beta-lactam allergy. *J Investig Allergol Clin Immunol*. 1996;6(2):89–93.
  24. Blanca M, Mayorga C, Torres MJ, Reche M, Moya C, Rodriguez JL, et al. Clinical evaluation of Pharmacia CAP System RAST FEIA amoxicilloyl and benzylpenicilloyl in patients with penicillin allergy. *Allergy*. 2001;56(9):862–70.
  25. Sanz ML, Gamboa PM, Antépara I, Uasuf C, Vila L, Garcia-Avilés C, et al. Flow cytometric basophil activation test by detection of CD63 expression in patients with immediate-type reactions to betalactam antibiotics. *Clin Exp Allergy*. 2002;32(2):277–86.
  26. Vultaggio A, Matucci A, Virgili G, Rossi O, Filì L, Parronchi P, et al. Influence of total serum IgE levels on the in vitro detection of  $\beta$ -lactams-specific IgE antibodies. *Clin Exp Allergy*. 2009;39(6):838–44.
  27. Vultaggio A, Virgili G, Gaeta F, Romano A, Maggi E, Matucci A. High serum  $\beta$ -lactams specific/total IgE ratio is associated with immediate reactions to  $\beta$ -lactams antibiotics. *PLoS One*. 2015;10(4):e0121857.
  28. Gil-Ocaña V, Jimenez IM, Mayorga C, Doña I, Céspedes JA, Montañez MI, et al. Multiepitope dendrimeric antigen-silica particle composites as nano-based platforms for specific recognition of IgEs. *Front Immunol*. 2021;3(12):5036.
  29. Quintero-Campos P, Juárez MJ, Morais S, Maquieira Á. Multiparametric highly sensitive chemiluminescence immunoassay for quantification of  $\beta$ -lactam-specific immunoglobulin E. *Anal Chem*. 2020;92(21):14608–15.
  30. Mas S, Badran AA, Juárez MJ, Fernández de Rojas DH, Morais S, Maquieira Á. Highly sensitive optoelectrical biosensor for multiplex allergy diagnosis. *Biosens Bioelectron*. 2020;166:112438.
  31. Juárez MJ, Ibáñez-Echevarria E, de Rojas DHE, Maquieira Á, Morais S. Multiplexed analytical approaches to beta-lactam allergy in vitro testing standardization. *Anal Chim Acta*. 2021;15(1173):338656.
  32. Ebo DG, Bridts CH, Mertens CH, Sabato V. Principles, potential, and limitations of ex vivo basophil activation by flow cytometry in allergology: a narrative review. *J Allergy Clin Immunol*. 2021;147(4):1143–53.

- 33 Santos AF, Alpan O, Hoffmann HJ. Basophil activation test: mechanisms and considerations for use in clinical trials and clinical practice. *Allergy: Eur J Allergy Clin Immunol.* 2021;76(8):2420–32.
34. • Elst J, Sabato V, van der Poorten MLM, Van Gasse AL, Van Houdt M, Bridts CH, et al. Basophil and mast cell activation tests by flow cytometry in immediate drug hypersensitivity: diagnosis and beyond. *J Immunol Methods.* 2021;1(495):113050.
- Review describes the principles of basophil and mast cell activation tests in the realm of drug hypersensitivity.
- 35 Steiner M, Harrer A, Himly M. Basophil reactivity as biomarker in immediate drug hypersensitivity reactions-potential and limitations. *Front Pharmacol.* 2016;7(JUN):171.
36. Mukai K, Gaudenzio N, Gupta S, Vivanco N, Bendall SC, Maecker HT, et al. Assessing basophil activation by flow cytometry and mass cytometry in blood stored 24 hours before analysis. *J Allergy Clin Immunol.* 2017;139(3):889.
37. Arribas Poves F, Falkencrone S, Sola J, Gomez-Serranillos MP, Laguna JJ, Montañez MI, et al. Basophil histamine release induced by amoxicilloyl-poly-L-lysine compared with amoxicillin in patients with IgE-mediated allergic reactions to amoxicillin. *J Investig Allergol Clin Immunol.* 2017;27(6):356–62.
38. Pineda F, Ariza A, Mayorga C, Arribas F, González-Mendiola R, Blanca-López N, et al. Role of histamine release test for the evaluation of patients with immediate hypersensitivity reactions to clavulanic acid. *Int Arch Allergy Immunol.* 2015;168(4):233–40.
39. Bahri R, Custovic A, Korosec P, Tsoumani M, Barron M, Wu J, et al. Mast cell activation test in the diagnosis of allergic disease and anaphylaxis. *J Allergy Clin Immunol.* 2018;142(2):485–496.e16.
40. Elst J, van der Poorten MLM, Faber MA, Van Gasse AL, Garvey LH, Bridts CH, et al. Mast cell activation test in chlorhexidine allergy: a proof of concept. *Br J Anaesth.* 2020;125(6):970–5.
41. • Zbären N, Brigger D, Bachmann D, Helbling A, Jörg L, Horn MP, et al. A novel functional mast cell assay for the detection of allergies. *J Allergy Clin Immunol.* 2022;149(3):1018–1030.e11.
- Novel mast cell activation test is based on an engineered cell line
42. Kumar M, Duraisamy K, Chow BK. Unlocking the non-IgE-mediated pseudo-allergic reaction puzzle with Mas-related G-protein coupled receptor member X2 (MRGPRX2). *Cells.* 2021;10(5):1033.
43. Pichler WJ, Tilch J. The lymphocyte transformation test in the diagnosis of drug hypersensitivity. *Allergy.* 2004;59(8):809–20.
44. Sachs B, Fatangare A, Sickmann A, Glässner A. Lymphocyte transformation test: history and current approaches. *J Immunol Methods.* 2021;1(493):113036.
45. Hammond S, Thomson P, Meng X, Naisbitt D. In-vitro approaches to predict and study T-cell mediated hypersensitivity to drugs. *Front Immunol.* 2021;13:12.
46. Sachs B, Fatangare A, Sickmann A, Glässner A. Lymphocyte transformation test: History and current approaches. *J Immunol Methods.* 2021;1(493):113036.
47. Weir C, Li J, Fulton R, Fernando SL. Development and initial validation of a modified lymphocyte transformation test (LTT) assay in patients with DRESS and AGEP. *Allergy Asthma Clin Immunol.* 2022;18(1):1–12.
48. Drygala S, Rdzanek E, Porebski G, Dubiela P. In vitro assays for diagnosis of drug-induced nonsevere exanthemas: a systematic review and meta-analysis. *J Immunol Res.* 2022;2386654.
49. Mayorga C, Doña I, Perez-Inestrosa E, Fernández TD, Torres MJ. The value of *in vitro* tests to diminish drug challenges. *Int J Mol Sci.* 2017;18(6):1222.
50. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. *Clin Pharmacol Ther.* 1981;30(2):239–45.
51. Fernandez-Santamaria R, Bogas G, Palomares F, Salas M, Fernandez TD, Jimenez I, et al. Dendritic cells inclusion and cell-subset assessment improve flow-cytometry-based proliferation test in non-immediate drug hypersensitivity reactions. *Allergy.* 2021;76(7):2123–34.
52. Srinoulprasert Y. Lymphocyte transformation test and cytokine detection assays: Determination of read out parameters for delayed-type drug hypersensitivity reactions. *J Immunol Methods.* 2021;496:113098.
53. Cabañas R, Calderón O, Ramírez E, Fiandor A, Caballero T, Heredia R, et al. Sensitivity and specificity of the lymphocyte transformation test in drug reaction with eosinophilia and systemic symptoms causality assessment. *Clin Exp Allergy.* 2018;48(3):325–33.
54. Glässner A, Dubrall D, Weinhold L, Schmid M, Sachs B. Lymphocyte transformation test for drug allergy detection: when does it work? *Ann Allergy Asthma Immunol.* 2022;129(4):497–506.e3.
55. Pichler WJ, Tilch J. The lymphocyte transformation test in the diagnosis of drug hypersensitivity. *Allergy.* 2004;59(8):809–20.
56. Porebski G, Pecaric-Petkovic T, Groux-Keller M, Bosak M, Kawabata TT, Pichler WJ. In vitro drug causality assessment in Stevens-Johnson syndrome – alternatives for lymphocyte transformation test. *Clin Exp Allergy.* 2013;43(9):1027–37.

57. Tang YH, Mockenhaupt M, Henry A, Bounoua M, Naldi L, Le Gouvello S, et al. Poor relevance of a lymphocyte proliferation assay in lamotrigine-induced Stevens-Johnson syndrome or toxic epidermal necrolysis. *Clin Exp Allergy*. 2012;42(2):248–54.
58. Fatangare A, Glässner A, Sachs B, Sickmann A. Future perspectives on in-vitro diagnosis of drug allergy by the lymphocyte transformation test. *J Immunol Methods*. 2021;1(495):113072.
- 59• Santos AF, Alpan O, Hoffmann HJ. Basophil activation test: mechanisms and considerations for use in clinical trials and clinical practice. *Allergy Eur J Allergy Clin Immunol*. 2021;76(8):2420–32. Review describes the principles of basophil activation tests, with its most relevant applications and limitations.
60. Torres J, Romano A, Mayorga C, Carmen M, Guzman AE, Reche M, et al. Diagnostic evaluation of a large group of patients with immediate allergy to penicillins: the role of skin testing. *Allergy*. 2001;56(9):850–6.
61. Uyttebroek AP, Sabato V, Bridts CH, De Clerck LS, Ebo DG. Immunoglobulin E antibodies to atracurium: a new diagnostic tool? *Clin Exp Allergy*. 2015;45(2):485–7.
62. Rouzaire P, Proton G, Bienvenu F, Guilloux L, Benoit Y, Piriou V, et al. IgE antibody detection in the diagnosis of hypersensitivity to neuromuscular blocking agents. *Acta Anaesthesiol Scand*. 2012;56(2):263–4.
63. Laroche D, Chollet-Martin S, Léturgie P, Malzac L, Vergnaud MC, Neukirch C, et al. Evaluation of a new routine diagnostic test for immunoglobulin E sensitization to neuromuscular blocking agents. *Anesthesiology*. 2011;114(1):91–7.
64. Garvey LH, Krøigaard M, Poulsen LK, Skov PS, Mosbech H, Venemalm L, et al. IgE-mediated allergy to chlorhexidine. *J Allergy Clin Immunol*. 2007;120(2):409–15.
65. Gamboa PM, García-Avilés MC, Urrutia I, Antépara I, Esparza R, Sanz ML. Basophil activation and sulfidoleukotriene production in patients with immediate allergy to betalactam antibiotics and negative skin tests. *J Investig Allergol Clin Immunol*. 2004;14(4):278–83.
66. Torres MJ, Padial A, Mayorga C, Fernandez T, Sanchez-Sabate E, Cornejo-Garcia JA, et al. The diagnostic interpretation of basophil activation test in immediate allergic reactions to betalactams. *Clin Exp Allergy*. 2004;34(11):1768–75.
67. De Week AL, Sanz ML, Gamboa PM, Aberer W, Sturm G, Bilo MB, et al. Diagnosis of immediate-type beta-lactam allergy in vitro by flow-cytometric basophil activation test and sulfidoleukotriene production: a multicenter study. *J Investig Allergol Clin Immunol*. 2009;19(2):91–109.
68. Eberlein B, Suárez IL, Darsow U, Ruëff F, Behrendt H, Ring J. A new basophil activation test using CD63 and CCR3 in allergy to antibiotics. *Clin Exp Allergy*. 2010;40(3):411–8.
69. Srinoulprasert Y, Rerkpattanapipat T, Sompornrat-anaphan M, Wongsu C, Kanistanon D. Clinical value of in vitro tests for the management of severe drug hypersensitivity reactions. *Asia Pac Allergy*. 2020;10(4):e44.
70. Abuaf N, Rostane H, Rajoely B, Gaouar H, Autegarden JE, Leynadier F, et al. Comparison of two basophil activation markers CD63 and CD203c in the diagnosis of amoxicillin allergy. *Clin Exp Allergy*. 2008;38(6):921–8.
71. García-Ortega P, Marín A. Usefulness of the basophil activation test (BAT) in the diagnosis of life-threatening drug anaphylaxis. *Allergy*. 2010;65(9):1204. <https://doi.org/10.1111/j.1398-9995.2010.02333.x>
72. Aranda A, Ariza A, Rosado A, Chaves P, Gomez E, Blanca N, et al. Basophil activation test for evaluating immediate allergic reactions to quinolones. *J Allergy Clin Immunol*. 2010;125(2):AB157.
73. Torres MJ, Ariza A, Fernández J, Moreno E, Laguna JJ, Montañez MI, et al. Role of minor determinants of amoxicillin in the diagnosis of immediate allergic reactions to amoxicillin. *Allergy*. 2010;65(5):590–6.
74. Torres MJ, Romano A, Blanca-Lopez N, Doña I, Canto G, Ariza A, et al. Immunoglobulin E-mediated hypersensitivity to amoxicillin: in vivo and in vitro comparative studies between an injectable therapeutic compound and a new commercial compound. *Clin Exp Allergy*. 2011;41(11):1595–601.
75. Céspedes JA, Fernández-Santamaría R, Ariza A, et al. Diagnosis of immediate reactions to amoxicillin: comparison of basophil activation markers CD63 and CD203c in a prospective study [published online ahead of print, 2022 Dec 7]. *Allergy*. 2022. <https://doi.org/10.1111/all.15610>
76. Heremans K, Toscano A, Elst J, Van Gasse AL, Mertens C, Beyens M, et al. Basophil activation test shows poor sensitivity in immediate amoxicillin allergy. *J Allergy Clin Immunol Pract*. 2023;11(2):500–5.
77. Salas M, Fernández-Santamaría R, Mayorga C, Barrionuevo E, Ariza A, Posadas T, et al. Use of the basophil activation test may reduce the need for drug provocation in amoxicillin-clavulanic allergy. *J Allergy Clin Immunol Pract*. 2018;6(3):1010–1018.e2.
78. Seitz CS, Bröcker EB, Trautmann A. Diagnostic testing in suspected fluoroquinolone hypersensitivity. *Clin Exp Allergy*. 2009;39(11):1738–45.
79. Lobera T, Audícana MT, Alarcón E, Longo N, Navarro B, Muñoz D. Allergy to quinolones: low cross-reactivity to levofloxacin. *J Investig Allergol Clin Immunol*. 2010;20(7):607–11.
80. Ben Said B, Berard F, Bienvenu J, Nicolas JF, Rozieres A. Usefulness of basophil activation tests

- for the diagnosis of IgE-mediated allergy to quinolones. *Allergy*. 2010;65(4):535–6.
81. Fernández TD, Ariza A, Palomares F, Montañez MI, Salas M, Martín-Serrano A, et al. Hypersensitivity to fluoroquinolones: the expression of basophil activation markers depends on the clinical entity and the culprit fluoroquinolone. *Medicine*. 2016;95(23):e3679.
  82. Abuaf N, Rajoely B, Ghazouani E, Levy DA, Pecquet C, Chabane H, et al. Validation of a flow cytometric assay detecting in vitro basophil activation for the diagnosis of muscle relaxant allergy☆☆☆. *J Allergy Clin Immunol*. 1999;104(2):411–8.
  83. Monneret G, Benoit Y, Debard AL, Gutowski MC, Topenot I, Bienvenu J. Monitoring of basophil activation using CD63 and CCR3 in allergy to muscle relaxant drugs. *Clin Immunol*. 2002;102(2):192–9.
  84. Sudheer PS, Hall JE, Read GF, Rowbottom AW, Williams PE. Flow cytometric investigation of peri-anaesthetic anaphylaxis using CD63 and CD203c. *Anaesthesia*. 2005;60(3):251–6.
  85. Kvedariene V, Kamey S, Ryckwaert Y, Rongier M, Bousquet J, Demoly P, et al. Diagnosis of neuromuscular blocking agent hypersensitivity reactions using cytofluorimetric analysis of basophils. *Allergy*. 2006;61(3):311–5.
  86. Hagau N, Gherman-Ionica N, Sfichi M, Petrisor C. Threshold for basophil activation test positivity in neuromuscular blocking agents hypersensitivity reactions. *Allergy Asthma Clin Immunol*. 2013;9(1):42.
  87. Li J, Best OG, Rose MA, Green SL, Fulton RB, Fernando SL. Integrating basophil activation tests into evaluation of perioperative anaphylaxis to neuromuscular blocking agents. *Br J Anaesth*. 2019;123(1):e135–43.
  88. Ebo DG, Bridts CH, Hagendorens MM, Mertens CH, De Clerck LS, Stevens WJ. Flow-assisted diagnostic management of anaphylaxis from rocuronium bromide. *Allergy*. 2006;61(8):935–9.
  89. Leysen J, Bridts CH, De Clerck LS, Vercauteren M, Lambert J, Weyler JJ, et al. Allergy to rocuronium: from clinical suspicion to correct diagnosis. *Allergy*. 2011;66(8):1014–9.
  90. Cop N, Uyttebroek AP, Sabato V, Bridts CH, De Clerck LS, Ebo DG. Flow cytometric analysis of drug-Induced basophil histamine release. *Cytometry B Clin Cytom*. 2016;90(3):285–8.
  91. Pinnobphun P, Buranapraditkun S, Kampitak T, Hirankarn N, Klaewsongkram J. The diagnostic value of basophil activation test in patients with an immediate hypersensitivity reaction to radiocontrast media. *Ann Allergy Asthma Immunol*. 2011;106(5):387–93.
  92. Salas M, Gomez F, Fernandez TD, et al. Diagnosis of immediate hypersensitivity reactions to radiocontrast media. *Allergy*. 2013;68(9):1203–1206. <https://doi.org/10.1111/all.12214>
  93. Giavina-Bianchi P, Galvão VR, Picard M, Caiado J, Castells MC. Basophil activation test is a relevant biomarker of the outcome of rapid desensitization in platinum compounds-allergy. *J Allergy Clin Immunol Pract*. 2017;5(3):728–36.
  94. Gamboa PM, Sanz ML, Caballero MR, Antepara I, Urrutia I, Jauregui I, et al. Use of CD63 expression as a marker of in vitro basophil activation and leukotriene determination in metamizol allergic patients. *Allergy*. 2003;58(4):312–7.
  95. Gómez E, Blanca-Lopez N, Torres MJ, Requena G, Rondon C, Canto G, et al. Immunoglobulin E-mediated immediate allergic reactions to dipyrone: value of basophil activation test in the identification of patients. *Clin Exp Allergy*. 2009;39(8):1217–24.
  96. Oehling A, Crisci C, Sanz M, Subirá M. Immunosuppressive effect of corticosteroids on rabbit's humoral and cellular response. *Allergol Immunopathol (Madr)*. 1976;4(4):255–8.
  97. Zhou J, Liu DF, Liu C, Kang ZM, Shen XH, Chen YZ, et al. Glucocorticoids inhibit degranulation of mast cells in allergic asthma via nongenomic mechanism. *Allergy*. 2008;63(9):1177–85.
  98. Savage JH, Courneya JP, Sterba PM, Macglashan DW, Saini SS, Wood RA. Kinetics of mast cell, basophil, and oral food challenge responses in omalizumab-treated adults with peanut allergy. *J Allergy Clin Immunol*. 2012;130(5):1123–1129. e2. <https://doi.org/10.1016/j.jaci.2012.05.039>

## Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.